| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.32 | 8e-11 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.25 | 6e-08 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.25 | 2e-07 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.25 | 7e-07 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.22 | 3e-05 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.19 | 0.0003 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.16 | 0.0009 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.097 | 0.05 |